Find clinical trials for Pancreatic Cancer in Rochester, MN
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Pancreatic Cancer trials near Rochester, MN, USA:
open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic...
Phase 1, Phase 2
Rochester, Minnesota, United States and 15 other locations
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS muta...
Phase 1
Rochester, Minnesota, United States and 22 other locations
to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor...
Phase 1
Rochester, Minnesota, United States and 21 other locations
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorect ...
Phase 1, Phase 2
Rochester, Minnesota, United States and 9 other locations
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors...
Phase 2
Rochester, Minnesota, United States and 71 other locations
This study is an open-label, international, multi-center, Phase 1 study in adult patients with solid tumors likely to express CLDN18.2....
Phase 1
Rochester, Minnesota, United States and 19 other locations
The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorec ...
Phase 1, Phase 2
Rochester, Minnesota, United States and 9 other locations
and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers...
Phase 2
Rochester, Minnesota, United States and 65 other locations
to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors...
Phase 2
Rochester, Minnesota, United States and 64 other locations
and Pharmacodynamic Study of Minnelide™Capsules given daily for 21 days followed by 7 days off schedule in patients with Advanced Solid Tumors...
Phase 1
Rochester, Minnesota, United States and 6 other locations
Clinical trials
Research sites
Resources
Legal